SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: Dan O. who wrote (4670)4/20/1998 1:40:00 AM
From: Peter Singleton  Read Replies (2) | Respond to of 9719
 
So, Dan, and this goes for Bernie as well, am I correct in hearing that you choose hold LGNDW over LGND given a set $ amount you want to invest in the company?

For example, if you want to hold $100 in your portfolio in Ligand, you'd choose LGNDW, not LGND.

If this is the case, you must be very confident that the downside risk is small, and the upside potential is high. Am I correct that this is implied in your decision? You're paying a premium to hold the warrants, and increasing your leverage.

That's a pretty aggressive bet on Ligand. It's one I might be inclined to support on the one hand because of the strength of their pipeline ... on the other hand, predicting price movements of individual biotechs in the short or intermediate term is a black art. As I've learned more than once ... : )

So, my question again, you must see limited downside, and substantial upside, to be willing to increase your leverage on your Ligand position. And you've done so factoring in a) the possibility of unexpected bad news from Ligand ... or what the market would interpret as such, b) the possibility of the market continuing to value the company well below its intrinsic value for a long time, c) the potential for a steep sell-off in the overall market.

I'm not questioning your decision, just want to understand it.

By way of disclosure, I have a significant holding in LGND, and no LGNDW.

Peter



To: Dan O. who wrote (4670)4/20/1998 5:23:00 AM
From: Henry Niman  Respond to of 9719
 
Dan, I think that Ligand's in house staff is closer to 350 than 400. However, the number of scientists at large pharmas working on Ligand projects is significant. The pipeline timeline (now linked to home.att.net ) can be accessed directly at home.att.net and many of the products in the research phase are grouped together or not even on the chart (and only two of the GLYC compounds are specifically listed).